Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Respondent characteristics by method of presentation

From: Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study

Respondent characteristics All respondents (n = 35,823) Method of presentation
PSA-detected (n = 11,210) Symptomatic (n = 21,378) Other (n = 1821) Unknown (n = 1414)
Age at diagnosis
  < 54 3.9% 4.0% 3.7% 5.7% 3.5%
 55-64 23.8% 24.4% 23.7% 26.1% 17.5%
 65-74 47.4% 48.9% 47.0% 46.1% 44.7%
 75+ 24.9% 22.7% 25.6% 22.1% 34.4%
Stage
 I/II 64.0% 71.2% 60.1% 65.3% 64.4%
 III 23.3% 22.0% 24.3% 20.7% 21.6%
 IV 12.7% 6.7% 15.6% 14.0% 14.0%
Gleason score
 2-6 29.0% 31.1% 27.7% 29.5% 30.8%
 7 47.3% 51.4% 45.3% 48.1% 45.0%
 8-10 23.7% 17.5% 27.0% 22.3% 24.2%
Treatment type a
 Any surgery 30.0% 31.9% 28.9% 31.8% 28.9%
 Any EBRT 38.9% 37.5% 40.4% 35.6% 32.5%
 Any brachytherapy 8.6% 10.7% 7.6% 7.7% 9.2%
 Any ADT 43.0% 37.0% 46.6% 42.3% 37.6%
 Any systemic 5.0% 2.5% 6.2% 5.7% 4.9%
 Any other 14.0% 15.0% 13.3% 12.4% 18.5%
 Monitoring only 16.8% 18.1% 15.9% 17.3% 20.2%
  1. Notes
  2. EBRT External Beam Radiotherapy, ADT Androgen Deprivation Therapy, Systemic - Chemotherapy/Abiraterone/Enzalutamide
  3. Additional respondent characteristics are available in Additional file 1: Table S2
  4. a Men may have more than one type of treatment